- Home
- HOOK vs DHAI Comparison
HOOK vs DHAI Comparison
Compare HOOK & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- DHAI
- Stock Information
- Founded
- HOOK 2011
- DHAI 2007
- Country
- HOOK United States
- DHAI United States
- Employees
- HOOK N/A
- DHAI N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- DHAI
- Sector
- HOOK Health Care
- DHAI
- Exchange
- HOOK Nasdaq
- DHAI NYSE
- Market Cap
- HOOK 11.9M
- DHAI 11.6M
- IPO Year
- HOOK 2019
- DHAI N/A
- Fundamental
- Price
- HOOK $0.89
- DHAI $0.25
- Analyst Decision
- HOOK Hold
- DHAI
- Analyst Count
- HOOK 3
- DHAI 0
- Target Price
- HOOK $4.50
- DHAI N/A
- AVG Volume (30 Days)
- HOOK 155.2K
- DHAI 2.7M
- Earning Date
- HOOK 08-11-2025
- DHAI 08-18-2025
- Dividend Yield
- HOOK N/A
- DHAI N/A
- EPS Growth
- HOOK N/A
- DHAI N/A
- EPS
- HOOK N/A
- DHAI N/A
- Revenue
- HOOK $9,351,000.00
- DHAI $69,573,000.00
- Revenue This Year
- HOOK N/A
- DHAI N/A
- Revenue Next Year
- HOOK N/A
- DHAI N/A
- P/E Ratio
- HOOK N/A
- DHAI N/A
- Revenue Growth
- HOOK N/A
- DHAI 5.40
- 52 Week Low
- HOOK $0.72
- DHAI $0.12
- 52 Week High
- HOOK $6.00
- DHAI $3.00
- Technical
- Relative Strength Index (RSI)
- HOOK 19.78
- DHAI 49.56
- Support Level
- HOOK $0.89
- DHAI $0.23
- Resistance Level
- HOOK $0.95
- DHAI $0.31
- Average True Range (ATR)
- HOOK 0.06
- DHAI 0.03
- MACD
- HOOK -0.01
- DHAI -0.00
- Stochastic Oscillator
- HOOK 7.11
- DHAI 39.42
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.